MATTHEW M. LOAR

Corporate Board Profile

Tech Score: 0/100

← Back to All Directors

Oncotelic Therapeutics, Inc.

Filing Date Source Excerpt
2016-10-03 Matthew M. Loar Includes 46,875 shares Mr. Loar has the right to acquire currently or within 60 days of September 15, 2016, upon the exercise of options.

Source material: SEC submissions metadata and DEF 14A proxy filings from EDGAR. Last updated: 2026-03-22